1. Market Research
  2. > Biotechnology Market Trends

The Russian Biopharmaceuticals and Biomedicine Market : From Import Substitution to Innovation

  • December 2014
  • 89 pages
  • Frost & Sullivan
Report ID: 2577020


Table of Contents

Executive Summary

•The Russian biopharmaceuticals market was valued at $ x billion in 2013 and is projected to grow at a CAGR of x % till 2018.
•The ageing population and increasing disease burden are key long-term growth factors for the biotech industry. By 2025, almost a quarter of the Russian population will be aged 60 years or more.
•The most sizable segments of the Russian biopharmaceuticals market include cytokines (interferons, erythropoietins), hormones, coagulants, protein kinase inhibitors, monoclonal antibodies (mAbs), vaccines, antibiotics, and bacteriophages.
•Key challenges for the biotech industry are associated with expected budget constraints as drug procurement moves to one-channel financing from the Federal Obligatory Medical Insurance Fund (FOMS).
•Russian companies, with the support of the government, are actively launching biosimilars, including monoclonal antibodies (mAbs), cytokines, and hormones. BIOCAD, R-Pharm, Generium, and Human Stem Cells Institute are emerging as national leaders in biopharmaceuticals and biomedicine.
•Biotechnology, nanotechnology, and Information Technology (IT), were prioritized by the Russian Government for the modernization of the Russian economy. The key focus is on import substitution of drugs from the List of Vital and Essential Drugs (ZHNVLP) and localization of manufacturing.
•Federal and regional authorities are creating a favorable environment for multinational corporations (MNCs) that localize production in Russia. In the biotech clusters, technoparks, and industrial parks that have been created, these companies can benefit from tax incentives and infrastructure access.
•The government has created a wide network of development institutions such as the Skolkovo Foundation, Russian Venture Company (RVC), and RUSNANO to support innovation, provide financing to biotech startups, and assist in transfer of technology from abroad.
•A network of scientific institutes of the Russian Academy of Sciences (RAS) and the Russian Academy of Medical Sciences (RAMS) concentrated in Moscow, St. Petersburg, and Novosibirsk are engaged in breakthrough research in the field of post-genomic technologies, bioinformatics, and new tools for diagnostics such as biochips and biosensors.
•The public-private partnership initiative—Technology Platform “Medicine of the Future”—is becoming an essential part in uniting academia and business efforts to launch innovative products in the Russian market.

Key Segments Include:

•Biopharmaceuticals (cytokines, hormones, coagulants, protein kinase inhibitors, monoclonal antibodies, vaccines, antibiotics, and bacteriophages);
•Biomedicine (cell technologies, gene therapy and regenerative medicine, nanomedicine and targeted drug delivery, biocompatible and biodegradable medical materials, diagnostic tools, biochips and biosensors, systems biology, post-genomic technologies, and bioinformatics).
•This study is mostly based on secondary research and is the result of a joint collaboration between Frost & Sullivan, Russian Venture Company, and the Moscow Exchange to increase investor awareness about the Russian biotechnology market.
•The key focus of research is to show the latest developments in Russian biotech, define key segments and emerging leaders, and outline government policies and support mechanisms.
•Due to the significant depreciation of the Russian currency in 2014 (particularly, September to November), market size and forecast estimations are defined in US Dollars (USD) and are based on the average USD to Russian Ruble (RUB) exchange rate of 2013, which is x rubles per dollar.
•Factors taken into consideration during forecasting include the ageing population, the dynamics of government spending on healthcare, investment by Russian and foreign companies, as well as an assumption that the share of biotechnology drugs in the total pharmaceutical market will increase, in line with global trends.
•The base year for the study is 2013 with a forecast period of 2014 to 2018.

Russian Economy Overview

•The general macroeconomic environment in Russia has continuously deteriorated in 2013–2014. Government attempts to diversify the economy have had little success. As a result, the Gross Domestic Product (GDP) growth is forecast to be within the x % to x % range in the next x years.
•The two major short-term factors that have a negative impact on the economy are political instability in Ukraine and sanctions imposed on Russia by western governments. This has already led to higher inflation expectations and depreciation of the Ruble against the Dollar and the Euro by x % and x %, respectively, in 2014 alone (as of end of October 2014).
•Though the official inflation and unemployment rates are relatively low, real indicators are considerably higher. Consumers are refraining from increasing consumption and have started to save, thus, leading to a negative impact on the entire economy.
•A decline in oil prices, as has been witnessed recently, could also severely impact the government budget and its obligations to maintain the level of healthcare financing it had reached before the financial crists of 2008.

Healthcare Market Overview

•At the end of September 2014, the government submitted a draft federal budget for 2015 and for a planned period of 2016–2017 to the State Duma (legislative branch). This is the first time that the budget considered the new territory of Crimea, as well as such factors as decreasing oil prices and possible consequences of sanctions imposed by the US and the European Union (EU) on Russia.
•The general federal spending on healthcare will decrease by x % in 2015 alone; however, this should be offset by the increase of financial inflow to the Federal Fund for the Obligatory Medical Insurance (FOMS) from employers’ contributions.
•In 2015, the FOMS budget is slated to increase by RUB x billion, in 2016 by RUB x billion, and in 2017 by RUB x billion. Total FOMS expenditure will constitute RUB x billion in 2015 ($ x billion), RUB x billion in 2016, and RUB x billion in 2017.
•The Ministry of Finance has proposed to eliminate contribution limits, starting in 2015. Currently employers pay x % of the payroll fund, not exceeding x ($ x ), for each employee per annum. The suggested reform seeks to remove this limit, thereby, taking into account every employee’s salary irrespective of what they earn.
•However, there is a major concern that in current economic conditions, employers will not be raising salaries; therefore, this could lead to a more widespread practice of under-the-table payments, which in turn, will result in an actual decrease in healthcare spending.
•It is worth noting that decreasing federal financing of healthcare is a long-term goal of the government in order to move to one-channel financing (from FOMS) and this is expected to give more autonomy to regional authorities and regional obligatory medical insurance funds.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026 Summary Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of ...

CAR-T Disease Outlook [2017]

  • $ 8355
  • Industry report
  • June 2017
  • by Firstword Pharma

Will CAR-T cell therapies shape the treatment of blood cancers in the next decade? Anti-CD19 CAR-T cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic ...

Biologics Outsourcing Global Market - Forecast to 2025

  • $ 7200
  • Industry report
  • August 2017
  • by IQ4I Research & Consultancy Pvt. Ltd

The biologics outsourcing global market is expected to grow at double digit CAGR to reach $70.3 billion by 2025. Biologics are therapeutic entities composed of sugars, proteins, or nucleic acids made from ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.